These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 36774991)

  • 41. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
    Veillette A; Chen J
    Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal.
    Li C; Liu Y; Li D; Wang Q; Zhou S; Zhang H; Wang Y; He Z; Liu H; Sun J
    Theranostics; 2022; 12(10):4581-4598. PubMed ID: 35832081
    [No Abstract]   [Full Text] [Related]  

  • 43. Modulating macrophage-mediated programmed cell removal: An attractive strategy for cancer therapy.
    Li Z; Han B; Qi M; Li Y; Duan Y; Yao Y
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189172. PubMed ID: 39151808
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils.
    Behrens LM; van den Berg TK; van Egmond M
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-SIRP
    Yanagita T; Murata Y; Tanaka D; Motegi SI; Arai E; Daniwijaya EW; Hazama D; Washio K; Saito Y; Kotani T; Ohnishi H; Oldenborg PA; Garcia NV; Miyasaka M; Ishikawa O; Kanai Y; Komori T; Matozaki T
    JCI Insight; 2017 Jan; 2(1):e89140. PubMed ID: 28097229
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
    Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
    Front Immunol; 2020; 11():18. PubMed ID: 32082311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy.
    Hazama D; Yin Y; Murata Y; Matsuda M; Okamoto T; Tanaka D; Terasaka N; Zhao J; Sakamoto M; Kakuchi Y; Saito Y; Kotani T; Nishimura Y; Nakagawa A; Suga H; Matozaki T
    Cell Chem Biol; 2020 Sep; 27(9):1181-1191.e7. PubMed ID: 32640189
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
    Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic modulation of the CD47-SIRPα axis in the pediatric tumor microenvironment: working up an appetite.
    Gupta A; Taslim C; Tullius BP; Cripe TP
    Cancer Drug Resist; 2020; 3(3):550-562. PubMed ID: 35582455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual-Action Protein-siRNA Conjugates for Targeted Disruption of CD47-Signal Regulatory Protein α Axis in Cancer Therapy.
    Lee JW; Yoon HY; Ko YJ; Kim EH; Song S; Hue S; Gupta N; Malin D; Kim J; Kong B; Kim S; Kim IS; Kwon IC; Yang Y; Kim SH
    ACS Nano; 2024 Aug; 18(33):22298-22315. PubMed ID: 39117621
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Versatile activatable vSIRPα-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells.
    Ko YJ; Lee JW; Kim H; Cho E; Yang Y; Kim IS; Kim SH; Kwon IC
    J Control Release; 2020 Jul; 323():376-386. PubMed ID: 32335154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glioblastoma Phagocytic Cell Death: Balancing the Opportunities for Therapeutic Manipulation.
    Du R; Tripathi S; Najem H; Brat DJ; Lukas RV; Zhang P; Heimberger AB
    Cells; 2024 May; 13(10):. PubMed ID: 38786045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
    Willingham SB; Volkmer JP; Gentles AJ; Sahoo D; Dalerba P; Mitra SS; Wang J; Contreras-Trujillo H; Martin R; Cohen JD; Lovelace P; Scheeren FA; Chao MP; Weiskopf K; Tang C; Volkmer AK; Naik TJ; Storm TA; Mosley AR; Edris B; Schmid SM; Sun CK; Chua MS; Murillo O; Rajendran P; Cha AC; Chin RK; Kim D; Adorno M; Raveh T; Tseng D; Jaiswal S; Enger PØ; Steinberg GK; Li G; So SK; Majeti R; Harsh GR; van de Rijn M; Teng NN; Sunwoo JB; Alizadeh AA; Clarke MF; Weissman IL
    Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6662-7. PubMed ID: 22451913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint.
    Wu ZH; Li N; Mei XF; Chen J; Wang XZ; Guo TT; Chen G; Nie L; Chen Y; Jiang MZ; Wang JT; Wang HB
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256517
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRPα axis.
    Chen XJ; Guo CH; Wang ZC; Yang Y; Pan YH; Liang JY; Sun MG; Fan LS; Liang L; Wang W
    Cell Commun Signal; 2024 Jan; 22(1):15. PubMed ID: 38183060
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma.
    Lu Q; Yang D; Li H; Zhu Z; Zhang Z; Chen Y; Yang N; Li J; Wang Z; Niu T; Tong A
    Cancer Lett; 2024 Mar; 585():216660. PubMed ID: 38266806
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
    Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
    J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
    Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
    Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Breaking the 'don't eat me' signal: in silico design of CD47-directed peptides for cancer immunotherapy.
    Laddha K; Sobhia ME
    Mol Divers; 2024 Oct; 28(5):3067-3083. PubMed ID: 37759140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
    Kazama R; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yoshida N; Kawamoto K; Yanagida E; Yamada K; Umeno T; Suzuki T; Kato K; Takizawa J; Seto M; Akashi K; Ohshima K
    Cancer Sci; 2020 Jul; 111(7):2608-2619. PubMed ID: 32342603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.